Results filtered:Study status:
Closed for Enrollment
A Phase 3 Global, Double-Blind, Randomized, Placebo‑Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin‑Mediated Amyloid Cardiomyopathy (ATTR CM) (ATTR CM)
To evaluate the effectiveness of AKCEA-TTR-LRx compared to placebo for 120 weeks in patients with ATTR-CM receiving available standard of care (SoC).
For more information, please visit https://www.cardio-ttransform.com/.
Long-term Monitoring of Patients with Cardiac Amyloidosis with Implantable Event Monitors
The primary purpose of this study is to assess arrhythmic events using the implantable cardiac monitor, Biomonitor 3, in subjects presenting to the clinic with TTR-wt cardiac amyloidosis.